The Medical Advisor

Patrick Soon-Shiong is back in the spotlight with early data from his Bioshield regimen in recurrent glioblastoma. The inventor of Abraxane and a transplant surgeon, Soon-Shiong says the approach could finally move the needle in one of oncology’s toughest indications. In a series of posts on X , the ImmunityBio executive chairman called glioblastoma “medicine’s biggest challenge,” pointing to decades of limited progress with surgery, radiation and chemotherapy. Standard regimens, he noted, in 90% of cases deplete lymphocytes, crippling NK and T cells and leaving patients prone to relapse. The new approach—described as a “chemo-free” combination of Bioshield (Cancer Vaccine*), NK cell therapy plus an immune-stimulating device—aims to protect and rescue the immune system rather than destroy it. *Note: Cancer vaccinations come in two varieties: preventative and therapeutic. Preventative vaccines allow the immune system to recognize an antigen and activate the immune system before deleteri...